Publication Topic

Su J, Bylsma LC, Jiang X, Morales Arias J, Jain N, Nordyke RJ. Healthcare resource utilization among commercially insured cold agglutinin disease patients in the United States. Poster presentation at International Society for Pharmacoeconomics and Outcomes Research, New Orleans, Louisiana, May 18–22, 2019.

Cronin-Fenton D, Dalvi T, Fryzek J, Hansen H, Hamilton-Dutoit S, Hedgeman E, Mellemgaard A, Norgaard M, Pedersen L, Potter D, Rasmussen TR, Rigas J, Shire N, Sorensen HT, Walker J. PD-L1 expression, EGFR and KRAS mustations in stage III unresectables non-small cell lung cancer (NSCLC) patients. Presented at the International Society for Pharmacoepidemiology Annual Conference, August 22-26, 2018, Prague, Czech Republic.

Ruzin A, Pastula ST, Levin-Sparenberg E, Jiang X, Fryzek J, Tovchigrechko A, Lu B, Qi Y, Liu H, Jin H, Yu L, Hackett J, Villafana T, Esser MT. 2018. Characterization of circulating RSV strains among subjects in the OUTSMART-RSV surveillance program during the 2016-17 winter viral season in the United States. PLoS One 13(7):e0200319.

Cronin-Fenton D, Dalvi T, Hedgeman E, Norgaard M, Pedersen L, Hansen H, Fryzek J, Walker J, Mellemgaard A, Rasmussen TR, Shire N, Rigas J, Potter D, Hamilton-Dutoit S, Sorensen HT. PD-L1 expression, EGFR and KRAS mustations in stage III unresectables non-small cell lung cancer (NSCLC) patients. Presented at the American Association for Cancer Research (AACR) Annual Meeting 2018, April 14-18, 2018, Chicago, IL.

Bylsma LC, Gulbech Ording A, Froslev T, Mehnert F, Fryzek JP, Morales Arias J, Roth A, Sorensen HT, Berentsen S. Occurrence, survival, and thromboembolic risk in cold agglutinin disease: a population-based cohort analysis. Presented at the 23rd Congress of the European Hematology Association, June 14-17 2018, Stockholm, Sweden.

Beebe-Dimmer JL, Ruterbusch JJ, Bylsma LC, Gillezeau C, Fryzek J, Schultz NM, Flanders SC, Barlev A, Heath E, Quek RGW. 2018. Patterns of bicalutamide use in prostate cancer treatment: A U.S. real-world analysis using the SEER-Medicare database. Adv Ther 35(1):1438-1451.

Schwartz KL, Simon MS, Bylsma LC, Ruterbusch JJ, Beebe-Dimmer JL, Schultz NM,  Flanders SC, Barlev A, Fryzek JP, Quek RGW. 2018. Clinical and economic burden associated with stage III to IV triple-negative breast cancer: A SEER-Medicare historical cohort study in elderly women in the United States. Cancer 124(10):2104-2114.

Bylsma LC, Gillezeau C, Garawin T, Kelsh M, Fryzek J, Sangare L, Lowe KA. Prevalence of RAS and BRAF Mutations in Metastatic Colorectal Cancer (mCRC) Patients by Tumor Location. Presented at the Gastrointestinal Cancers Symposium, January 18-20, 2018, San Francisco, CA.

Fryzek JP, Reichert H, Summers N, Townes L, Deuson R, Alexander DD, Vanderpuye-Orgle J. 2018. Indirect treatment comparison of cabazitaxel for patients with metastatic castrate-resistant prostate cancer who have been previously treated with a docetaxel-containing regimen. PLoS One 13(4):e0195790.

Mullins M, Jiang X, Bylsma LC, Fryzek JP, Reichert H, Chen EC, Kummar S, Rosenthal A. 2017. Cold agglutinin disease burden: A longitudinal analysis of anemia, medications, transfusions, and healthcare utilization. Blood Adv 1:839-848.